United Therapeutics | UTHR - Interest Expense On Debt


United Therapeutics reported $3.1M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Amarin USD 3K 5K Dec/2024
Ardelyx USD 5.8M 784K Sep/2025
Baxter International USD 58M 14M Sep/2025
Bayer EUR 675M 87M Dec/2025
BioCryst Pharmaceuticals USD 24.45M 381K Dec/2024
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.78M 199K Dec/2025
Esperion Therapeutics USD 15.08M 1.36M Sep/2024
Gilead Sciences USD 255M 1000K Dec/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
Halozyme Therapeutics USD 4.91M 615K Dec/2025
Insmed USD 20.6M 217K Dec/2025
Ionis Pharmaceuticals USD 18M 0 Dec/2025
J&J USD 18M 290M Sep/2025
Lexicon Pharmaceuticals USD 2.21M 2.74M Jun/2024
Moderna USD 12.14B 12.13B Sep/2025
Omeros USD 4.05M 5.16M Sep/2024
Pfizer USD 711M 59M Dec/2025
PTC Therapeutics USD 50.58M 2.59B Dec/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Teva Pharmaceutical Industries USD 220M 17M Dec/2025
United Therapeutics USD 3.1M 100K Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025